Phase 2 N=13 Treatment for Calcium Phosphate Kidney Stone Disease
Calcium Phosphate Kidney Stones
Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=13 Effect of Cola on Urinary Stone Risk Factors
Kidney Stone
Primary: The Plasma and Urine Parameters — 6800; 6800; 3700; 3700 mg per dL
N/A N=3 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
N/A N=12 Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Chronic Kidney Disease
Primary: Calcium Balance — 61; 508 mg/d calcium
Phase 2 N=241 Adding Phosphorus to Osteoporosis Drug Treatment
Osteoporosis · Osteopenia
Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2
Phase 4 N=29 Vitamin D Repletion in Stone Formers With Hypercalciuria
Nephrolithiasis · Urolithiasis · Idiopathic Hypercalciuria
Primary: Change in 24 Hour Urine Calcium — 2 mg/day
Phase 3 N=416 Hydrochlorothiazide for Kidney Stone Recurrence Prevention
Nephrolithiasis
Primary: Number of Participants With Stone Recurrences — 60; 62; 61; 49 Participants
N/A N=16 Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
Chronic Kidney Disease
Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml
Phase 2 N=99 Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
Hyperuricosuria · Kidney Stones
Primary: Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion — -58.6; -36.4; -12.7 percent change — p=<0.001
Phase 3 N=19 Phentermine/Topiramate for Uric Acid Stones
Obesity · Uric Acid Stones · Type 2 Diabetes Mellitus in Obese
Primary: Kidney Stone Size (mm^3) Determined by Non-contrast CAT Scan — 6540; 4650; 3120; 5041 mm^3
Phase 2 N=16 Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Hyperoxaluria · Nephrolithiasis
Primary: Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion — -13.92 mg/day
Phase 3 N=30 Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]
Phase 2 N=20 Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
Cystinuria · Nephrolithiasis, Calcium Oxalate
Primary: 24 Hour Urine Supersaturation of Calcium Oxalate (CaOx) — 1.83; 1.83; 1.87; 1.78 KJoules/mol — p=0.32
Phase 4 N=38 Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
Chronic Kidney Disease
Primary: Serum Phosphorus Levels — 4.6; 4.6 mg/dL
N/A N=58 Obesity and Endogenous Oxalate Synthesis
Obesity
Primary: Urinary Oxalate Excretion — 24 mg/day
Phase 2 N=10 The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria
Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…
Phase 3 N=151 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Hyperphosphatemia · End-Stage Renal Disease
Primary: Change in Serum Phosphorus From Baseline to End of Treatment — -0.10; -1.86; -2.13 mg/dL — p=<0.0001
N/A N=145 A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
Chronic Kidney Disease
Primary: Serum Phosphorus — 3.9; 4.2 mg/dL
Phase 4 N=83 The Effects of Potassium Citrate on Bone Metabolism
Bone Diseases, Metabolic · Osteoporosis, Postmenopausal
Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine
N/A N=31 Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23
Albuminuria
Primary: 24-hour Urine Albumin Excretion — 86.2; 76.4 mg/day — p=0.05
Phase 2 N=61 Bone Mass and Strength After Kidney Transplantation
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
Phase 1 N=55 Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants
Calcium Deficiency · Vitamin D Deficiency
Primary: Amount of Calcium Excreted in Urine From 0 Hours up to 6 Hours Post Dose (Ca2+ Ae0-6h) — 1.07; 0.63 mmol
Phase 4 N=44 Vitamin D and Coronary Calcification Study
Chronic Kidney Disease · Vitamin D Deficiency · Coronary Calcification
Primary: Coronary Artery (CAC) Score Progression — 74.38; 106.32 Agatston units
Phase 3 N=35 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Hemodialysis · Hyperphosphatemia
Primary: Incidence of Adverse Events — 28 Participants
N/A N=26 Racial Differences in Phosphorus Metabolism
Control
Primary: Urinary Phosphorus Excretion — 11 percentage of fractional excretion
Phase 4 N=61 Phosphate Lowering in CKD Trial
Chronic Kidney Disease · Cardiovascular Disease
Primary: Brachial Artery Flow-mediated Dilation — 3.13; 3.74; 2.73; 3.09 percent change FMD
Phase 4 N=41 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
Chronic Kidney Disease, Stage 5 · Secondary Hyperparathyroidism
Primary: Calcium Absorption Fractions Analyzed by Analysis of Variance (ANOVA) — 0.103; 0.108 Fractions — p=0.573
Phase 4 N=110 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Confirmed Hypercalcemia — 3; 1 participants — p=0.36
N/A N=43 Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline